Edlund A, Wennmalm A
Department of Clinical Physiology, Huddinge Hospital, Sweden.
Clin Physiol. 1990 Nov;10(6):585-90. doi: 10.1111/j.1475-097x.1990.tb00450.x.
Endothelin (ET-1) is a recently discovered endothelial-derived peptide with pronounced vasoconstrictor activity. The present study addressed whether ET-1, in analogy with several other vasoactive agents, can induce or modulate aggregation of human platelets in vitro. Venous blood from healthy donors was collected in citrate or heparin and platelet-rich plasma (PRP) was prepared. Portions of the PRP were added to drugs, and platelet aggregation was recorded according to Born & Cross (1963). ET-1 added to the PRP (final concentrations 1-100 nM) did not induce aggregation of platelets, either in citrate- or heparin-containing plasma. Adenosine-diphosphate (0.5-2 microM) or thrombin (0.1-0.4 NIH units ml-1) induced dose-dependent aggregation of platelets in citrate- or heparin-containing PRP; such aggregation was, however, not affected by ET-1 (1-100 microM) either. We conclude that ET-1, in contrast to other endothelial-derived vasoactive agents, lacks direct effect on platelet aggregation in vitro.
内皮素(ET-1)是最近发现的一种具有显著血管收缩活性的内皮衍生肽。本研究探讨了ET-1是否与其他几种血管活性物质类似,能在体外诱导或调节人血小板的聚集。从健康供体采集的静脉血用柠檬酸盐或肝素抗凝,并制备富含血小板血浆(PRP)。将部分PRP加入药物中,根据Born和Cross(1963年)的方法记录血小板聚集情况。在含柠檬酸盐或肝素的血浆中,加入到PRP中的ET-1(终浓度1 - 100 nM)均未诱导血小板聚集。二磷酸腺苷(0.5 - 2 microM)或凝血酶(0.1 - 0.4 NIH单位/ml-1)在含柠檬酸盐或肝素的PRP中诱导血小板呈剂量依赖性聚集;然而,这种聚集也不受ET-1(1 - 100 microM)的影响。我们得出结论,与其他内皮衍生的血管活性物质不同,ET-1在体外对血小板聚集缺乏直接作用。